Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey

Journal of Chemotherapy

Volumn 17, Issue 4, 2005, Pages 380-384

  Senol, Gunes ^a,b   Erbaycu, A ^a   Ozsoz A ^a  

^a Izmir Chest Diseases and Surgery Training Hospital   (Turkey)

^b NONE   (Turkey)

Author keywords

Drug resistance; Rifabutin; Rifampicin; Tuberculosis

Indexed keywords

AGAR; RIFABUTIN; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CROSS RESISTANCE; DILUTION; HUMAN; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TURKEY (REPUBLIC);

EID: 24644462834     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.4.380     Document Type: Article

References (33)

1. Yuen LK, Leslie D, Cole PJ. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol 1999; 37 (12): 3844-3850.
2. Pfyffer GE, Bonato DA, Ebrahimzadeh A et al. Multicenter laboratory validation of testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37 (10): 3179-3186.
3. Heifets LB, Linholm-Levy PJ, Iseman MD. Rifabutin: Minimum inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis 1988; 137 (3): 719-721.
4. Della Bruna C, Olliaro P. Setting breakpoints for assessing the sensitivity of mycobacteria to rifabutin in vitro. J Antimicrobial Chem 1994; 34 (1): 184-186.
5. Farr BM: Rifamycins. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone. 1995: 318-25.
6. Uzun M, Erturan Z, Ang O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 2002; 6 (2): 164-165.
7. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996; 22 Suppl. 1: S3-14.
8. Heifets LB, Iseman MD. Determination of in vitro susceptibility of Mycobacteria to ansamycin. Am Rev Respir Dis 1985; 132 (3): 710-711.
9. Hershfield EB: Tuberculosis. Treatment. Can Med Assoc J 1999; 161 (4): 405-411.
10. Luna-Herrera J, Reddy MV, Gandgadharam PR. In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli. J Antimicrob Chem 1995; 36 (2): 355-363.
11. Yew WW, Chau CH. New antimycobacterial agents. Mon Arch Chest Dis 1996; 51 (5): 394-404.
12. World Health Organization: Global tuberculosis control: surveillance, planning, financing: WHO report 2004: 171.
13. Loddenkemper R, Sagebiel D, Brendel A. Strategies against multidrug-resistant tuberculosis. Eur Respir J 2002; 20 Suppl 1: 66-77.
14. Kisa O, Albay A, Baylan O et al. Drug resistance in Mycobacterium tuberculosis: a retrospective study from a 2000-bed teaching hospital in Ankara, Turkey. Int J Antimicrob Agents 2003; 22 (4): 465-457.
15. Öztürkeri H, Emekdas G, Kocabeyoglu Ö et al. In-vitro efficiency of isoniazid, rifampin, ethambutol and streptomycin against tuberculosis bacilli: Results of Bactec method. J Turk Microbiol Soc 1999; 29: 58-60.
16. Senol G, Kömürcüoglu B, Kömürcüoglu A. Drug resistance of Mycobacterium tuberculosis in Western Turkey: a retrospective study from 1100 bed teaching hospital. Doi: 10.1016/j.jinf.2004.05.010.
17. Erkan L, Sipit T, Akkalyoncu B, Gözü A et al. Cross resistance between rifampin and rifabutin [in Turkish]. J Respir Dis 2000; 11: 396-400.
18. Saribas Z, Kocagöz T, Alp A et al. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heterodublex analysis and determination of rifamycin cross resistance in rifampin resistance isolates. J Clin Microbiol 2003; 41 (2): 816-818.
19. Kent PT, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. Centers for Disease Control, Atlanta, GA. 1985.
20. Heifets LB. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis 1988; 137 (5): 1217-1222.
21. Sintchenko V, Chew WK, Jelfs PJ et al. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology 1999; 31 (3): 257-260.
22. Pubhlik BM. Problem of drug-resistant tuberculosis and the way of its solution [In Russian]. Probl Tuberk 1999; 6: 17-20.
23. De Cian W, Sassela D, Wynne BA. Clinical experience with rifabutin in the treatment of mycobacterial infections. Scand J Infect Dis 1995; 98: 22-26.
24. Frieden TR, Sterling T, Pablos-Mendez A et al. The emergence of drug-resistance tuberculosis in New York City. N Engl J Med 1993; 328 (2): 521-526.
25. Dickinson JM, Mitchison DA. In vitro activity of new rifamycin against rifampin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68 (3): 177-182.
26. Chien HP, Yu MC, Ong TF et al. In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan. J Form Med Assoc 2000; 99 (5): 408-411.
27. Ridzon R, Whitney CG, McKenna MT et al. Risk factors for rifampin mono-resistant tuberculosis. Am Rev Respir Dis 1998; 157 (6 Pt 1): 1881-1884.
28. Cavusoglu C, Karaca-Derici Y, Bilgiç A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10 (7): 602-605.
29. Yang B, Koga H, Ohna H et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrobial Chem 1998; 42 (4): 621-628.
30. Jabes D. Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis. Antimicrobial Agents Chem 1994; 38 (10): 2346-2350.
31. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Rifabutin study group. Tuberc Lung Dis 1994; 75 (3): 341-347.
32. Bergmann JS, Woods GL. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1998; 2 (8): 621-626.
33. Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22 Suppl 1: 50-54.